AMENDMENTS TO THE CLAIMS

1. (Original) A human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

2. (Original) A polynucleotide encoding the human solid cancer antigenic polypeptide according to claim 1.

3. (Original) A polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 46, 47, 49, 51, 53, 55, 57, 58, 60, 62, 64, 66, 68, 70, 72, and 74.

4. (Original) A diagnostic kit for solid cancer comprising a means of detecting the expression of at least one human solid cancer antigenic polypeptide in a sample derived from a subject, characterized in that the human solid cancer antigenic polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

5. (Original) A diagnostic kit for solid cancer comprising a means of detecting the expression of at least one human solid cancer antigenic polypeptide in a sample derived from a subject, characterized in that the human solid cancer antigenic polypeptide is encoded by a

polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 46, 47, 49, 51, 53, 55, 57, 58, 60, 62, 64, 66, 68, 70, 72, and 74.

6. (Currently amended) The diagnostic kit for solid cancer according to claim 4 ~~or 5~~, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is the solid cancer antigenic polypeptide or a partial peptide thereof.

7. (Currently amended) The diagnostic kit for solid cancer according to claim 4 ~~or 5~~, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is an antibody against the solid cancer antigenic polypeptide.

8. (Currently amended) The diagnostic kit for solid cancer according to claim 4 ~~or 5~~, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is a primer or probe comprising a polynucleotide consisting of the entire or a partial sequence of a polynucleotide encoding the solid cancer antigenic polypeptide or a complementary sequence thereof.

9. (Currently amended) The diagnostic kit for solid cancer according to ~~any one of claims 4 to 8~~ claim 4, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is immobilized on a solid phase.

10. (Currently amended) The diagnostic kit for solid cancer according to ~~any one of claims 4 to 9~~ claim 4, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is labeled.

11. (Currently amended) The diagnostic kit for solid cancer according to ~~any one of claims 4 to 10~~ claim 4, wherein the solid cancer is selected from the group consisting of colorectal cancer, esophageal cancer, gastric cancer, and breast cancer.

12. (Currently amended) The diagnostic kit for solid cancer according to ~~any one of claims 4 to 11~~ claim 4, wherein the sample is selected from the group consisting of serum, blood, hemocytes, and tissue.

13. (Original) A medicament for preventing or treating solid cancer comprising a means of inhibiting the functions or expression of at least one human solid cancer antigenic polypeptide, characterized in that the human solid cancer antigenic polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

14. (Original) A medicament for preventing or treating solid cancer comprising a means of inhibiting the functions or expression of at least one human solid cancer antigenic polypeptide, characterized in that the human solid cancer antigenic polypeptide is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID

NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 46, 47, 49, 51, 53, 55, 57, 58, 60, 62, 64, 66, 68, 70, 72, and 74.

15. (Currently amended) The medicament according to claim 13 ~~or 14~~, wherein the means of inhibiting the functions or expression of the human solid cancer antigenic polypeptide is an antibody against the solid cancer antigenic polypeptide.

16. (Currently amended) The medicament according to claim 13 ~~or 14~~, wherein the means of inhibiting the functions or expression of the human solid cancer antigenic polypeptide is a means capable of inhibiting transcription of a gene encoding the solid cancer antigenic polypeptide.

17. (Currently amended) The medicament according to claim 13 ~~or 14~~, wherein the means of inhibiting the functions or expression of the human solid cancer antigenic polypeptide is a means capable of inhibiting translation of a gene encoding the solid cancer antigenic polypeptide.

18. (Original) A medicament for preventing or treating solid cancer comprising a gene encoding a prophylactic or therapeutic agent for solid cancer and a means of targeting to human solid cancer.

19. (Original) The medicament according to claim 18, wherein the means of targeting to human solid cancer is an antibody against a solid cancer antigenic polypeptide.

20. (Original) The medicament according to claim 18, wherein the means of targeting to human solid cancer is a nucleotide sequence of an expression control region of a polynucleotide encoding a solid cancer antigenic polypeptide.